JAMA Intern Med

Multivitamins offer no CV benefit post MI in patients with diabetes

March 6, 2025

High-dose oral multivitamins and multiminerals (OMVMs) alone or with edetate disodium (EDTA)–based chelation, doesn't reduce CV events in diabetic patients post myocardial infarction (MI).

Study design: The randomized, multicenter, double-masked 2×2 factorial TACT2 trial (NCT02733185) was conducted across 88 sites in the U.S. and Canada. It included 1,000 participants aged 50 years or older with diabetes and a history of MI. Participants were randomized to receive either a 28-component OMVM or placebo, along with EDTA-based chelation therapy or placebo, in a 1:1:1:1 ratio.

Results: After a median follow-up of 48 months, the primary endpoint (composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina) occurred in 35% of both the active OMVM and placebo groups (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.80-1.22; P = 0.92). Comparison of active infusion + active OMVM with placebo infusion + placebo OMVM was also not significant (HR, 0.91; 95% CI, 0.67-1.23; P = 0.54).

Source:

Ujueta F; TACT2 Investigators, et al. (2025, March 3). JAMA Intern Med. Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40029647/